From a market sentiment view, the "AZN stock forecast" is supported by recent FDA approvals for new oncology treatments. This fundamental catalyst has led several investment banks to revise their earnings projections upward, anticipating solid free cash flow in the next two quarters. Most members of the Magnificent Seven stocks advanced in pre-market trading, with Tesla (TSLA) and Nvidia (NVDA) rising over +1%. Shares of Merck MRK have rallied almost 14% so far this week as investors’ optimism grew concerning the broader pharmaceutical sector in the United States after Pfizer PFE announced a landmark deal with the Trump administration. The deal aims to reduce prescription drug costs while boosting investment in U.S.-based innovation and manufacturing. The "AZN stock forecast" also reflects potential upside from upcoming phase III trial results due in late summer
